Generic drug firms are facing a tougher business environment. In efforts to cut spending, some European countries, have recently reduced the prices they pay for generics. As a result, generic makers are less likely to bid for the contracts, which has allowed the makers of branded drugs to secure the contracts and make a profit […]
Biologics will account for seven of the top 10 selling drugs in five years and half of the top 100 selling drugs, according to EvaluatePharma. Last year, five of the 10 top selling drugs were biologics and 28% of the top 100 were biologics. Of the biologics in the top 5 in 2014, five are […]
Updating its 2008 R&D survey (see IBO 12/31/08), Battelle and R&D Magazine now estimate that total R&D spending for 40 countries will grow 1.6% to $1.125 trillion this year, compared to the earlier estimate of a 3.2% increase. The update accounts for stimulus plans and the continuing recession. A survey of readers of four magazines […]
The incidence of cancer in the US is estimated to increase 45% between 2010 and 2030 to approximately 2.3 million people, according to a study published in the Journal of Clinical Oncology. A 67% increase in cancer in adults age 65 or older and a 99% increase in minorities are primarily responsible for the overall […]
A report prepared by RTI International describes the success of the National Institute of Standards and Technology’s (NIST) Combinatorial Methods Center (NCMC) in advancing technology development and assisting industry. Launched in 2002, the NCMC was charged with providing technology for combinatorial and high-throughput experimentation for organic polymers, disseminating research and establishing a scientific forum. Structured […]
Medicare has proposed not to pay for tests to determine the proper dose of wafarin for a patient due to insufficient evidence of their effectiveness compared to current methods. The genetic tests costs $50–$500. However, Medicare stated it would pay for the tests in clinical trials. The public may comment on the proposal for one […]
Although German GDP fell 6.7% in the first quarter on an annual basis, one would not have suspected it from the convention floor at ACHEMA 2009, which took place from May 11 to 15 in Frankfurt am Main. The various halls that compose the Messe Frankfurt exhibition grounds thronged with visitors and exhibitors. Total attendance […]
US President Barack Obama’s fiscal 2010 budget proposal includes a 0.4% increase in R&D spending over the fiscal 2009 enacted level to $147.6 billion. Funding for basic research would increase 3.4% to $30.9 billion, and spending for development would rise 0.2% to $84.1 billion. Funding for applied research would decline 2.2% to $28.1 billion. R&D […]
According to the World Steel Association, global steel demand will decrease 14.9% in 2009. This is in addition to the drop in output and profits currently plaguing the steel sector. In 1997, the last time demand for steel declined, demand fell 2.7%. The last double-digit decline was in 1945. Global steel production and consumption is […]
There were 356 responses to the 2009 Food Processing R&D survey. The most important target for R&D this year for 48% of those surveyed was new product development, up from less than a third of respondents last year. For 30%, existing product improvement was the most important target. However, according to 63% of respondents, product […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
